It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Glioma stem cells (GSC) exhibit plasticity in response to environmental and therapeutic stress leading to tumor recurrence, but the underlying mechanisms remain largely unknown. Here, we employ single-cell and whole transcriptomic analyses to uncover that radiation induces a dynamic shift in functional states of glioma cells allowing for acquisition of vascular endothelial-like and pericyte-like cell phenotypes. These vascular-like cells provide trophic support to promote proliferation of tumor cells, and their selective depletion results in reduced tumor growth post-treatment in vivo. Mechanistically, the acquisition of vascular-like phenotype is driven by increased chromatin accessibility and H3K27 acetylation in specific vascular genes allowing for their increased expression post-treatment. Blocking P300 histone acetyltransferase activity reverses the epigenetic changes induced by radiation and inhibits the adaptive conversion of GSC into vascular-like cells and tumor growth. Our findings highlight a role for P300 in radiation-induced stress response, suggesting a therapeutic approach to prevent glioma recurrence.
Therapeutic stress induces phenotypic plasticity in glioma stem cells although the mechanisms underlying this remain poorly understood. Here, the authors show that P300 mediates the radiation-induced vascular-like conversion of glioma stem cells to promote tumor recurrence.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 The UCLA Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, UCLA, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
2 University of Michigan Medical School, Department of Neurosurgery, and Department of Cell and Developmental Biology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
3 David Geffen School of Medicine, UCLA, Division of Cardiology, Department of Medicine, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
4 David Geffen School of Medicine, UCLA, Department of Neurology, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
5 David Geffen School of Medicine, UCLA, Department of Radiation Oncology, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
6 Mayo Clinic, Department of Neurological Surgery, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
7 University of Rochester Medical Center, Center for Translational Neuromedicine, Rochester, USA (GRID:grid.412750.5) (ISNI:0000 0004 1936 9166); University of Coppenhagen School of Medicine, Center for Translational Neuromedicine, Coppenhagen, Denmark (GRID:grid.412750.5)
8 The UCLA Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, UCLA, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718); David Geffen School of Medicine, UCLA, Department of Neurology, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
9 The UCLA Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, UCLA, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718); David Geffen School of Medicine, UCLA, Department of Molecular and Medical Pharmacology, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)